Combinations Alliance EOI Calls - Verastem

We are delighted to announce that Verastem have joined the Combinations Alliance. Verastem are the fifth partner to offer their agents to the ECMC Network through this initiative and we look forward to a successful collaboration with them.

In the first instance, Verastem are offering VS-6063 from their portfolio. VS-6063 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Combination studies with other novel agents are sought. Current interests include immune checkpoint antibodies and Cdk4/6 inhibitors but the company is open to other novel combinations with scientific rationale.

Please refer to the non-confidential data package for further details.

If your second novel agent of choice is not currently available within the Combinations Alliance Portfolio, we will contact companies of interest on your behalf.

We welcome EOI proposals that require additional preclinical work. These proposals will be discussed with the company with opportunities for direct funding or application to the NAC preclinical funding stream.

EOIs that are clinic ready, require access to an additional compound for the proposed combination or additional preclinical evidence are invited to be submitted on the EOI template (see also accompanying guidelines) to the Combinations Alliance mailbox by the 16th February 2015. We hope this will be of interest to the ECMC Network and look forward to receiving your EOIs.

Summary of key dates